iCEMIGE: Integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers

Figure 4 Prognostic value of iCEMIGE score on overall survival and progress-free survival according to ER status and tumor stage. A: Kaplan-Meier curves on overall survival (OS) (top panel) and progress-free survival (PFS) (bottom panel) for ER+ and ER- breast cancer (BC) patients are presented according to iCEMIGE score groups; B: Kaplan-Meier curves on OS (top panel) and PFS (bottom panel) for Stage I, II, and III&IV BC patients are presented according to iCEMIGE score groups. The P values were obtained from the log-rank test among the three groups.